BPG is committed to discovery and dissemination of knowledge
Featured Articles
1/22/2025 10:07:00 AM | Browse: 310 | Download: 687
 |
Received |
|
2024-08-11 13:30 |
|
Peer-Review Started |
|
2024-08-11 13:30 |
|
First Decision by Editorial Office Director |
|
2024-12-17 09:57 |
|
Return for Revision |
|
2024-12-17 09:57 |
|
Revised |
|
2024-12-18 13:46 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-12-25 02:46 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-12-25 07:37 |
|
Articles in Press |
|
2024-12-25 07:37 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-01-06 03:14 |
|
Publish the Manuscript Online |
|
2025-01-22 09:26 |
| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Programmed cell death receptor 1 inhibitor Pembrolizumab in the treatment of advanced gastric cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xue-Mei Yi, Hong-Qiao Cai and Yan Jiao |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Jilin Provincial Natural Science Foundation |
No. YDZJ202401650ZYTS |
|
| Corresponding Author |
Yan Jiao, MD, PhD, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com |
| Key Words |
Programmed cell death receptor 1 inhibitor; Pembrolizumab; Advanced gastric cancer; Chemotherapy; Trastuzumab |
| Core Tip |
In the past decade, programmed cell death receptor 1 (PD-1) inhibitors have shown significant anti-tumor effects and good safety in the treatment of various malignant tumors such as melanoma and non-small cell lung cancer. Multiple studies on advanced gastric cancer have shown that the combination therapy of PD-1 inhibitors can improve the efficacy. Pembrolizumab combined with chemotherapy or human epidermal growth factor receptor 2 targeting therapy have showed improved prognosis. In the future, it is important to explore the reasonable treatment sequence and dosage, to maximize the efficacy of combination therapy. |
| Publish Date |
2025-01-22 09:26 |
| Citation |
Yi XM, Cai HQ, Jiao Y. Programmed cell death receptor 1 inhibitor Pembrolizumab in the treatment of advanced gastric cancer. World J Gastrointest Surg 2025; 17(2): 100257 |
| URL |
https://www.wjgnet.com/1948-9366/full/v17/i2/100257.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v17.i2.100257 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
